Plasma concentrations of 5‐(4‐hydroxyphenyl)‐5‐phenylhydantoin in phenytoin‐treated patients
- 1 March 1977
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 21 (3) , 294-300
- https://doi.org/10.1002/cpt1977213294
Abstract
A mass fragmentographic method was used to determine unconjugated and conjugated 5-(4-hydroxyphenyl)-5-phenylhydantoin (4-OH-DPH) in plasma of patients being treated with phenytoin (DPH). The plasma concentration of unconjugated 4-OH-DPH is stable at steady-state for DPH and the level does not change during the dose interval. Most patients (82.5%) have plasma concentrations of unconjugated 4-OH-DPH between 0.04 and 0.2 µg/ml at concentrations of DPH between 5 and 30 µg/ml. Interindividual differences in the ratio between plasma concentration of unconjugated 4-OH-DPH and DPH were noted in a wide range of doses. Dosage adjustments of DPH in patients were not associated with major changes in the plasma level of unconjugated 4-OH-DPH. The plasma concentration of conjugated 4-OH-DPH also showed interindividual differences and varied between 1.2 and 4.5 µg/ml in patients with DPH concentrations between 5 and 30 µg/ml. The data are consistent with the concept of Michaelis-Menten kinetics for DPH metabolism.This publication has 2 references indexed in Scilit:
- Loading and conventional dose therapy with phenytoin in children: Kinetic profile of parent drug and main metabolite in plasmaClinical Pharmacology & Therapeutics, 1976
- Acute Intoxication with 5,5-Diphenylhydantoin (Dilantin®) Associated with Impairment of BiotransformationAnnals of Internal Medicine, 1972